Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ. Toomey S, et al. Among authors: madden sf. Oncotarget. 2016 Nov 15;7(46):75518-75525. doi: 10.18632/oncotarget.12782. Oncotarget. 2016. PMID: 27776352 Free PMC article.
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
Coté D, Eustace A, Toomey S, Cremona M, Milewska M, Furney S, Carr A, Fay J, Kay E, Kennedy S, Crown J, Hennessy B, Madden S. Coté D, et al. Among authors: madden s. PLoS One. 2018 Aug 2;13(8):e0200996. doi: 10.1371/journal.pone.0200996. eCollection 2018. PLoS One. 2018. PMID: 30071039 Free PMC article. Clinical Trial.
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
Elster N, Toomey S, Fan Y, Cremona M, Morgan C, Weiner Gorzel K, Bhreathnach U, Milewska M, Murphy M, Madden S, Naidoo J, Fay J, Kay E, Carr A, Kennedy S, Furney S, Mezynski J, Breathhnach O, Morris P, Grogan L, Hill A, Kennedy S, Crown J, Gallagher W, Hennessy B, Eustace A. Elster N, et al. Among authors: madden s. Ther Adv Med Oncol. 2018 Jul 13;10:1758835918778297. doi: 10.1177/1758835918778297. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30023006 Free PMC article.
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
Eustace AJ, Madden SF, Fay J, Collins DM, Kay EW, Sheehan KM, Furney S, Moran B, Fagan A, Morris PG, Teiserskiene A, Hill AD, Grogan L, Walshe JM, Breathnach O, Power C, Duke D, Egan K, Gallagher WM, O'Donovan N, Crown J, Toomey S, Hennessy BT. Eustace AJ, et al. Among authors: madden sf. Breast Cancer Res Treat. 2021 Jun;187(3):635-645. doi: 10.1007/s10549-021-06244-1. Epub 2021 May 13. Breast Cancer Res Treat. 2021. PMID: 33983492 Free PMC article.
581 results